eSpraye (Pulmonary fibrosis, Dry Powder) - Onyx Analyst
Dr. Adil Ali asks Dr. John Patton (CSO) and Dan Miller (Formulation Development Lead) all about eSpraye's drug pipeline.
Eric Schlumpf, President & CEO, Stuart Therapeutics | Onyx Live | JPM 2026
Stuart Therapeutics is testing the first collagen mimetic peptide for dry eye disease – a novel mechanism that produced Week 1 staining gains vs. vehicle greater than any reported result for an approved therapy in their recent Phase 3.
Stuart Lowe, Head of Advanced Therapies, TTP | Onyx Live | Advanced Therapies 2026
A single CAR-T dose still takes up to 33 days to manufacture, at $170,000–$220,000 per batch.
The sugar layer biotech forgot - and why Anomer Bio thinks small molecules can finally drug it
Co-founder and CEO Sophie James on modified monosaccharides, intracellular glycan processing, and a rare-disease-first route into fibrosis, oncology, and Alzheimer's.
Stuart Curbishley, Chief Development & Manufacturing Officer, adthera bio | Onyx Live | Advanced Therapies 2026
Stuart Curbishley on how adthera bio is tackling the biggest bottleneck in cell and gene therapy: getting therapies manufactured at scale.
Miguel Forte, President, International Society for Cell & Gene Therapy | Onyx Live | Advanced Therapies 2026
Venture investment in cell and gene therapy has crashed by nearly $8 billion since 2021's peak, putting the field's translation to patients at risk.
Alexander Seyf, CEO, Autolomous | Onyx Live | Advanced Therapies 2026
With over 2,000 cell and gene therapies in clinical trials globally, the industry’s reliance on manual, labour-intensive manufacturing is an existential bottleneck.
Marinna Madrid, Co-Founder, Cellino | Onyx Live | JPM 2026
With zero FDA-approved personalised iPSC therapies on the market, the vast majority of patients who could benefit from regenerative treatments still can’t access them.
FDA approvals - March 2026
New options emerged in PBC-associated itch, plaque psoriasis, neurologic Hunter syndrome, and platinum-resistant ovarian cancer.
FDA approves Rocket's Kresladi as the first gene therapy for severe leukocyte adhesion deficiency-I
The first gene therapy for severe LAD-I achieves 100% HSCT-free survival with sustained CD18 expression through 42 months in paediatric patients lacking a matched donor
Brad Sitko, CIO, XOMA Royalty | Onyx Live | JPM 2026
The biotech industry destroys billions in shareholder value every year - failed trials, depleted cash, and abandoned pipelines leaving investors with nothing.
Avi Veidman, CEO, Nucleai | Onyx Live | JPM 2026
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now.
Will biotech still be relevant in 2030? | Treehill Partners Ep. 3 | JPM 2026
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model?
Paul Denslow, CEO, Intus Bio | Onyx Live | JPM 2026
38 trillion bacteria live in your gut — yet most microbiome tests can only identify them at the genus level, missing the strains that actually matter.
Mike Cordonnier, CEO, Carlsmed | Onyx Live | JPM 2026
Hundreds of thousands of spine fusions are performed each year, but implant choice is still often limited to standard sizes.
Chris Hall, CEO, Personalis | Onyx Live | JPM 2026
Personalis is betting that detecting relapse at the molecular level, before it becomes radiographically obvious, can change how cancer is monitored and managed.